临终关怀中抗生素处方与生存的关系
本研究纳入2017年6月20日至2023年1月1日某大型医疗系统门诊临终关怀项目的6169例患者,评估抗生素使用与生存的关系。采用时间依赖Cox模型校正年龄、性别、Charlson合并症指数和临终关怀资格条件,发现抗生素使用与死亡风险增加相关(aHR 1.47;95%CI 1.37-1.57),但按资格条件分层后,癌症患者死亡风险增加(aHR 1.67;95%CI 1.50-1.87),感染相关资格条件患者生存获益(aHR 0.60;95%CI 0.40-0.89)。
要点
- 临终关怀患者抗生素使用与死亡风险增加相关(aHR 1.47)。
- 癌症资格条件患者使用抗生素死亡风险更高(aHR 1.67)。
- 感染资格条件患者使用抗生素显示生存获益(aHR 0.60)。
核心结论
- 临终关怀患者抗生素使用与死亡风险增加相关,但该关联因临终关怀资格条件而异。
研究设计与样本
- 回顾性队列研究,纳入某大型医疗系统门诊临终关怀项目2017年6月20日至2023年1月1日期间6169例患者。
- 采用时间依赖Cox比例风险模型,校正年龄、性别、Charlson合并症指数和临终关怀资格条件。
主要发现
- 6169例患者中1233例至少接受一次抗菌药物处方,从入组到首次处方中位时间16天(IQR 3-83)。
- 抗生素使用与死亡风险增加相关(aHR 1.47;95%CI 1.37-1.57)。
- 癌症资格条件患者死亡风险增加(aHR 1.67;95%CI 1.50-1.87)。
- 感染资格条件患者显示生存获益(aHR 0.60;95%CI 0.40-0.89)。
临床怎么用
- 临终关怀中启动抗生素后短期死亡风险增加,提示症状可能反映濒死过程而非可治疗感染。
- 应结合临终关怀资格条件评估抗生素获益,癌症患者尤其需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: At hospice enrollment, patients are asked preferences regarding antibiotic use. Limited evidence on how these medications impact survival makes it difficult for clinicians to offer clear guidance. To support decision-making and antimicrobial stewardship, we assessed the association between antibiotic use and survival in outpatient hospice patients. METHODS: The association between antibiotic use and survival was evaluated using a time-dependent Cox proportional hazards model, adjusted for age, sex, Charlson Comorbidity Index, and hospice-qualifying conditions (HQCs). The cohort included patients enrolled in a large health system's outpatient hospice program between June 20, 2017, and January 1, 2023. RESULTS: Among 6169 patients with an HQC, 1233 received at least one antimicrobial prescription during the study period. The median time from hospice enrollment to first prescription was 16 days (IQR 3-83). Antimicrobial prescribing patterns varied by HQC category. In time-dependent Cox models, antibiotic use was associated with increased hazard of death (aHR 1.47; 95% confidence interval [CI], 1.37-1.57).Stratified analyses showed the strongest association with increased mortality in patients with cancer HQCs (aHR 1.67; 95% CI, 1.50-1.87) and a survival benefit in those with infectious HQCs (aHR 0.60; 95% CI, 0.40-0.89). DISCUSSION: Physicians, patients, and families often overestimate the benefits of antibiotics near the end of life. The observed increase in mortality shortly after antibiotic initiation suggests that symptoms prompting antibiotic use may reflect the dying process rather than treatable infection. Knowledge of the limited role of antibiotics in prolonging life in hospice settings may improve decision-making and enhance the quality of end-of-life care.
引用
- Crowley PD, Siegel LR, Dickinson DT, et al. Relationship between Antibiotic Prescription and Survival in Hospice. Clin Infect Dis. 2026. PMID: 42725640. doi:10.1093/cid/ciag561
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。